Ge Bai

HSAs allow patients to benefit from lower prices and better health, reduce risks to medical debt, and offer tax advantages. All Americans should have access to HSAs.

The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse incentives for the biopharma industry.

CMS’s debt relief approach, devoid of accountability to taxpayers and riddled with harmful incentives, will worsen medical debt. It’s time to focus on fixing root causes.

Although gender-affirming care is a decision made by the patients in consultation with physicians, it is also funded by employers, other beneficiaries, and taxpayers.

The U.S.'s dominance in biotech innovation is critical to our national interests; yet, our government policies are undermining American advantages against China.

Vice President Kamala Harris announced her proposal for Medicare to cover long-term at-home healthcare for seniors. The fiscal challenge of this proposal is monumental.

U.S. nonprofit hospitals enjoyed a total annual tax benefit of $37.4 billion. Policymakers have been tilting the playing field in favor of them for too long.

We should fund patients, not the system, for IVF treatments. Wrong policies, such as funding providers or mandating insurance coverage, will inevitably fail patients.

Government-centered healthcare is fundamentally anticompetitive, anti-innovation, undemocratic, and contrary to the American self-governed way of life.

Instead of adopting counterproductive Band-Aid policies such as debt cancellation, Congress should unleash American dynamism in healthcare for the benefit of all.